Literature DB >> 18774276

Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial.

A Diehl1, I Reinhard, A Schmitt, K Mann, W F Gattaz.   

Abstract

BACKGROUND: Tardive dyskinesia (TD) is a movement disorder observed after chronic neuroleptic treatment. Smoking is presumed to increase the prevalence of TD. The question of a cause-effect-relationship between smoking and TD, however, remains to be answered. Purpose of this study was to examine the correlation between the degree of smoking and the severity of TD with respect to differences caused by medication.
METHOD: We examined 60 patients suffering from schizophrenia and TD. We compared a clozapine-treated group with a group treated with typical neuroleptics. Movement disorders were assessed using the Abnormal-Involuntary-Movement-Scale and the technical device digital image processing, providing rater independent information on perioral movements.
RESULTS: We found a strong correlation (.80<r<.90, always p<.0001) between the degree of smoking and severity of TD. Repeated measurements revealed a positive correlation between changes in cigarette consumption and changes of the severity of TD (p<.0001). Analyses of covariance indicated a significant group-effect with a lower severity of TD in the clozapine-group compared to the typical-neuroleptics-group (p=.010). Interaction-analyses indicated a higher impact of smoking on the severity of TD in the typical-neuroleptics-group compared to the clozapine-group (p=.033).
CONCLUSION: Concerning a possible cause-effect-relationship between smoking and TD, smoking is more of a general health hazard than neuroleptic exposure in terms of TD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774276     DOI: 10.1016/j.eurpsy.2008.07.007

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  6 in total

1.  Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2011-12-05       Impact factor: 4.030

2.  Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

Authors:  Scott W Woods; Hal Morgenstern; John R Saksa; Barbara C Walsh; Michelle C Sullivan; Roy Money; Keith A Hawkins; Ralitza V Gueorguieva; William M Glazer
Journal:  J Clin Psychiatry       Date:  2010-02-09       Impact factor: 4.384

3.  Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.

Authors:  Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2013-08-21       Impact factor: 4.530

4.  Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Jincai He; Wei Cheng; Zhiwei Wu; Fu De Yang; Colin N Haile; Hongqiang Sun; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

5.  Withdrawal-Emergent Dyskinesias following Varenicline Therapy.

Authors:  Brittany A Toffey; Marcie Rabin; Roger Kurlan
Journal:  Open Neurol J       Date:  2015-05-29

6.  Effect of Varenicline on Tardive Dyskinesia: A Pilot Study.

Authors:  Stanley N Caroff; Alisa R Gutman; John Northrop; Shirley H Leong; Rosalind M Berkowitz; E Cabrina Campbell
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.